OncoMatch/Clinical Trials/NCT05783622
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Is NCT05783622 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JANX008 for non-small cell lung cancer.
Treatment: JANX008 — This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Small Cell Lung Cancer
Pancreatic Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Prior therapy
Must have received: all available therapies known to confer clinical benefit appropriate for the tumor type
Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for the tumor type
Cannot have received: EGFR-targeted bispecific T cell engager
Prior treatment with EGFR-targeted bispecific T cell engager
Cannot have received: CAR-T cell therapy
Prior treatment with EGFR-targeted bispecific T cell engager or CAR-T cell therapy
Cannot have received: CD3 engaging bispecific antibody
Prior treatment with CD3 engaging bispecific antibodies
Cannot have received: anti-cancer therapy
Exception: within 28 days or ≤5 elimination half-lives, whichever is earlier, before enrollment
Treatment with anti-cancer therapy within 28 days or ≤5 elimination half-lives, whichever is earlier, before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- University of California, Davis Comprehensive Cancer Center · Sacramento, California
- University of California San Diego Moores Cancer Center · San Diego, California
- Winship Cancer Institute, Emory University · Atlanta, Georgia
- University of Chicago Medical Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify